ENANTA PHARMACEUTICALS INC - 8-K Filing
Enanta Pharmaceuticals reported Q2 fiscal results ending March 31, 2026, with revenue at $17.2 million (up from $14.9 million YoY), driven by royalties on AbbVie's MAVYRET/MAVIRET sales. The company recorded a net loss of $13.1 million ($0.45 per diluted share) compared to $22.6 million ($1.06 per diluted share) in the prior year period, with R&D expenses at $19.4 million and cash reserves totaling $227 million as of March 31. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $ENTA